Sign in to edit your profile (add interests, mentoring, photo, etc.)
    Keywords
    Last Name
    Institution

    Girish J Kotwal PhD

    TitleProfessor
    InstitutionUniversity of Massachusetts Medical School
    DepartmentMedicine
    AddressUniversity of Massachusetts Medical School
    364 Plantation Street, LRB-327
    Worcester MA 01605
    Phone508-856-5982
        Bibliographic 
        selected publications
        List All   |   Timeline
        1. Kotwal GJ, Hatch S, Marshall WL. Viral infection: an evolving insight into the signal transduction pathways responsible for the innate immune response. Adv Virol. 2012; 2012:131457.
          View in: PubMed
        2. Kulkarni AP, Kellaway LA, Kotwal GJ. Application of quartz crystal microbalance with dissipation monitoring technology for studying interactions of poxviral proteins with their ligands. Methods Mol Biol. 2012; 890:289-303.
          View in: PubMed
        3. Rus F, Morlock K, Silverman N, Pham N, Kotwal GJ, Marshall WL. Characterization of Poxvirus-Encoded Proteins that Regulate Innate Immune Signaling Pathways. Methods Mol Biol. 2012; 890:273-88.
          View in: PubMed
        4. Kulkarni AP, Govender D, Kellaway LA, Kotwal GJ. Central nervous system distribution of the poxviral proteins after intranasal administration of proteins and titering of vaccinia virus in the brain after intracranial administration. Methods Mol Biol. 2012; 890:305-26.
          View in: PubMed
        5. Kotwal GJ. Complement-initiated neuroinflammation and its role in early stage Alzheimer's disease. Commentary. Curr Alzheimer Res. 2011 Feb 1; 8(1):32-3.
          View in: PubMed
        6. Kulkarni AP, Govender DA, Kotwal GJ, Kellaway LA. Modulation of anxiety behavior by intranasally administered vaccinia virus complement control protein and curcumin in a mouse model of Alzheimer's disease. Curr Alzheimer Res. 2011 Feb 1; 8(1):95-113.
          View in: PubMed
        7. Kotwal GJ. Influence of glycosylation and oligomerization of vaccinia virus complement control protein on level and pattern of functional activity and immunogenicity. Protein Cell. 2010 Dec; 1(12):1084-92.
          View in: PubMed
        8. Sundararajan A, Ganapathy R, Huan L, Dunlap JR, Webby RJ, Kotwal GJ, Sangster MY. Influenza virus variation in susceptibility to inactivation by pomegranate polyphenols is determined by envelope glycoproteins. Antiviral Res. 2010 Oct; 88(1):1-9.
          View in: PubMed
        9. Kulkarni AP, Randall PJ, Murthy K, Kellaway LA, Kotwal GJ. Investigation of interaction of vaccinia virus complement control protein and curcumin with complement components c3 and c3b using quartz crystal microbalance with dissipation monitoring technology. Open Biochem J. 2010; 4:9-21.
          View in: PubMed
        10. Ghebremariam YT, Engelbrecht G, Tyler M, Lotz Z, Govender D, Kotwal GJ, Kahn D. Vaccinia virus complement control protein (VCP) improves kidney structure and function following ischemia/reperfusion injury in rats. J Surg Res. 2010 Apr; 159(2):747-54.
          View in: PubMed
        11. Thorgersen EB, Pharo A, Haverson K, Axelsen AK, Gaustad P, Kotwal GJ, Sfyroera G, Mollnes TE. Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood. Infect Immun. 2009 Feb; 77(2):725-32.
          View in: PubMed
        12. Mathew A, O'Bryan J, Marshall W, Kotwal GJ, Terajima M, Green S, Rothman AL, Ennis FA. Robust intrapulmonary CD8 T cell responses and protection with an attenuated N1L deleted vaccinia virus. PLoS One. 2008; 3(10):e3323.
          View in: PubMed
        13. Kulkarni AP, Pillay NS, Kellaway LA, Kotwal GJ. Intracranial administration of vaccinia virus complement control protein in Mo/Hu APPswe PS1dE9 transgenic mice at an early age shows enhanced performance at a later age using a cheese board maze test. Biogerontology. 2008 Dec; 9(6):405-20.
          View in: PubMed
        14. Pillay NS, Kellaway LA, Kotwal GJ. Early detection of memory deficits and memory improvement with vaccinia virus complement control protein in an Alzheimer's disease model. Behav Brain Res. 2008 Oct 10; 192(2):173-7.
          View in: PubMed
        15. Kotwal GJ. Genetic diversity-independent neutralization of pandemic viruses (e.g. HIV), potentially pandemic (e.g. H5N1 strain of influenza) and carcinogenic (e.g. HBV and HCV) viruses and possible agents of bioterrorism (variola) by enveloped virus neutralizing compounds (EVNCs). Vaccine. 2008 Jun 6; 26(24):3055-8.
          View in: PubMed
        16. Pillay NS, Kellaway LA, Kotwal GJ. Vaccinia virus complement control protein significantly improves sensorimotor function recovery after severe head trauma. Brain Res. 2007 Jun 11; 1153:158-65.
          View in: PubMed
        17. Habte HH, Kotwal GJ, Lotz ZE, Tyler MG, Abrahams M, Rodriques J, Kahn D, Mall AS. Antiviral activity of purified human breast milk mucin. Neonatology. 2007; 92(2):96-104.
          View in: PubMed
        18. Kaur A, Kamboj SS, Singh J, Singh R, Abrahams M, Kotwal GJ, Saxena AK. Purification of 3 monomeric monocot mannose-binding lectins and their evaluation for antipoxviral activity: potential applications in multiple viral diseases caused by enveloped viruses. Biochem Cell Biol. 2007 Feb; 85(1):88-95.
          View in: PubMed
        19. Thorgersen EB, Ghebremariam YT, Thurman JM, Fung M, Nielsen EW, Holers VM, Kotwal GJ, Mollnes TE. Candidate inhibitors of porcine complement. Mol Immunol. 2007 Mar; 44(8):1827-34.
          View in: PubMed
        20. Abdul Ajees A, Gunasekaran K, Volanakis JE, Narayana SV, Kotwal GJ, Murthy HM. The structure of complement C3b provides insights into complement activation and regulation. Nature. 2006 Nov 9; 444(7116):221-5.
          View in: PubMed
        21. Kotwal GJ. Avian Influenza in Humans--First Annual Conference. Latest advances on prevention, therapies and protective measures. 29-30 June 2006, Paris, France. IDrugs. 2006 Sep; 9(9):625-6.
          View in: PubMed
        22. Liszewski MK, Leung MK, Hauhart R, Buller RM, Bertram P, Wang X, Rosengard AM, Kotwal GJ, Atkinson JP. Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J Immunol. 2006 Mar 15; 176(6):3725-34.
          View in: PubMed
        23. Thorbjornsdottir P, Kolka R, Gunnarsson E, Bambir SH, Thorgeirsson G, Kotwal GJ, Arason GJ. Vaccinia virus complement control protein diminishes formation of atherosclerotic lesions: complement is centrally involved in atherosclerotic disease. Ann N Y Acad Sci. 2005 Nov; 1056:1-15.
          View in: PubMed
        24. Abrahams MR, Zhang Z, Chien S, Skerns T, Kotwal GJ. The vaccinia virus N1L ORF may encode a multifunctional protein possibly targeting different kinases, one of which influences ATP levels in vivo. Ann N Y Acad Sci. 2005 Nov; 1056:87-99.
          View in: PubMed
        25. Gomes Pereira NA, Juliano MA, Carmona AK, Sturrock ED, Kotwal GJ. Cloning and expression of a functionally active truncated N-glycosylated KSHV ORF4/KCP/kaposica in the methylotrophic yeast Pichia pastoris. Ann N Y Acad Sci. 2005 Nov; 1056:388-404.
          View in: PubMed
        26. Ghebremariam YT, Odunuga OO, Janse K, Kotwal GJ. Humanized recombinant vaccinia virus complement control protein (hrVCP) with three amino acid changes, H98Y, E102K, and E120K creating an additional putative heparin binding site, is 100-fold more active than rVCP in blocking both classical and alternative complement pathways. Ann N Y Acad Sci. 2005 Nov; 1056:113-22.
          View in: PubMed
        27. Kotwal GJ, Kaczmarek JN, Leivers S, Ghebremariam YT, Kulkarni AP, Bauer G, De Beer C, Preiser W, Mohamed AR. Anti-HIV, anti-poxvirus, and anti-SARS activity of a nontoxic, acidic plant extract from the Trifollium species Secomet-V/anti-vac suggests that it contains a novel broad-spectrum antiviral. Ann N Y Acad Sci. 2005 Nov; 1056:293-302.
          View in: PubMed
        28. Pillay NS, Kellaway LA, Kotwal GJ. Administration of vaccinia virus complement control protein shows significant cognitive improvement in a mild injury model. Ann N Y Acad Sci. 2005 Nov; 1056:450-61.
          View in: PubMed
        29. Kulkarni AP, Kellaway LA, Kotwal GJ. Herbal complement inhibitors in the treatment of neuroinflammation: future strategy for neuroprotection. Ann N Y Acad Sci. 2005 Nov; 1056:413-29.
          View in: PubMed
        30. Ballardin M, Scarpato R, Kotwal GJ, Barale R. In vitro mutagenicity studies of the antiretrovirals AZT, Didanosine, and 3TC and a plant antiviral extract Secomet-V derived from the Trifollium species. Ann N Y Acad Sci. 2005 Nov; 1056:303-10.
          View in: PubMed
        31. Jha P, Smith SA, Justus DE, Kotwal GJ. Vaccinia virus complement control protein ameliorates collagen-induced arthritic mice. Ann N Y Acad Sci. 2005 Nov; 1056:55-68.
          View in: PubMed
        32. Zhang Z, Abrahams MR, Hunt LA, Suttles J, Marshall W, Lahiri DK, Kotwal GJ. The vaccinia virus N1L protein influences cytokine secretion in vitro after infection. Ann N Y Acad Sci. 2005 Nov; 1056:69-86.
          View in: PubMed
        33. Kulkarni AP, Ghebremariam YT, Kotwal GJ. Curcumin inhibits the classical and the alternate pathways of complement activation. Ann N Y Acad Sci. 2005 Nov; 1056:100-12.
          View in: PubMed
        34. Ghebremariam YT, Smith SA, Anderson JB, Kahn D, Kotwal GJ. Intervention strategies and agents mediating the prevention of xenorejection. Ann N Y Acad Sci. 2005 Nov; 1056:123-43.
          View in: PubMed
        35. Ganesh VK, Muthuvel SK, Smith SA, Kotwal GJ, Murthy KH. Structural basis for antagonism by suramin of heparin binding to vaccinia complement protein. Biochemistry. 2005 Aug 16; 44(32):10757-65.
          View in: PubMed
        36. Kulkarni AP, Kellaway LA, Lahiri DK, Kotwal GJ. Neuroprotection from complement-mediated inflammatory damage. Ann N Y Acad Sci. 2004 Dec; 1035:147-64.
          View in: PubMed
        37. Billings B, Smith SA, Zhang Z, Lahiri DK, Kotwal GJ. Lack of N1L gene expression results in a significant decrease of vaccinia virus replication in mouse brain. Ann N Y Acad Sci. 2004 Dec; 1030:297-302.
          View in: PubMed
        38. Reynolds DN, Smith SA, Zhang YP, Mengsheng Q, Lahiri DK, Morassutti DJ, Shields CB, Kotwal GJ. Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury. Ann N Y Acad Sci. 2004 Dec; 1035:165-78.
          View in: PubMed
        39. Pillay NS, Kellaway LA, Kotwal GJ. Molecular mechanisms, emerging etiological insights and models to test potential therapeutic interventions in Alzheimer's disease. Curr Alzheimer Res. 2004 Nov; 1(4):295-306.
          View in: PubMed
        40. DiPerna G, Stack J, Bowie AG, Boyd A, Kotwal G, Zhang Z, Arvikar S, Latz E, Fitzgerald KA, Marshall WL. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem. 2004 Aug 27; 279(35):36570-8.
          View in: PubMed
        41. Ganesh VK, Smith SA, Kotwal GJ, Murthy KH. Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation. Proc Natl Acad Sci U S A. 2004 Jun 15; 101(24):8924-9.
          View in: PubMed
        42. Kotwal GJ. HIV treatment and eradication in South Africa. J R Soc Med. 2004 Jan; 97(1):1-2.
          View in: PubMed
        43. Kotwal GJ, Abrahams MR. Growing poxviruses and determining virus titer. Methods Mol Biol. 2004; 269:101-12.
          View in: PubMed
        44. Jha P, Smith SA, Justus DE, Kotwal GJ. Prolonged retention of vaccinia virus complement control protein following IP injection: implications in blocking xenorejection. Transplant Proc. 2003 Dec; 35(8):3160-2.
          View in: PubMed
        45. Lahiri DK, Chen D, Ge YW, Farlow M, Kotwal G, Kanthasamy A, Ingram DK, Greig NH. Does nitric oxide synthase contribute to the pathogenesis of Alzheimer's disease?: effects of beta-amyloid deposition on NOS in transgenic mouse brain with AD pathology. Ann N Y Acad Sci. 2003 Dec; 1010:639-42.
          View in: PubMed
        46. Reynolds DN, Smith SA, Zhang YP, Lahiri DK, Morassutti DJ, Shields CB, Kotwal GJ. Vaccinia virus complement control protein modulates inflammation following spinal cord injury. Ann N Y Acad Sci. 2003 Dec; 1010:534-9.
          View in: PubMed
        47. Smith SA, Sreenivasan R, Krishnasamy G, Judge KW, Murthy KH, Arjunwadkar SJ, Pugh DR, Kotwal GJ. Mapping of regions within the vaccinia virus complement control protein involved in dose-dependent binding to key complement components and heparin using surface plasmon resonance. Biochim Biophys Acta. 2003 Aug 21; 1650(1-2):30-9.
          View in: PubMed
        48. Kahn D, Smith SA, Kotwal GJ. Dose-dependent inhibition of complement in baboons by vaccinia virus complement control protein: implications in xenotransplantation. Transplant Proc. 2003 Jun; 35(4):1606-8.
          View in: PubMed
        49. Anderson JB, Smith SA, van Wijk R, Chien S, Kotwal GJ. Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation. Transpl Immunol. 2003 Apr-Jun; 11(2):129-35.
          View in: PubMed
        50. Jha P, Kotwal GJ. Vaccinia complement control protein: multi-functional protein and a potential wonder drug. J Biosci. 2003 Apr; 28(3):265-71.
          View in: PubMed
        51. Scott MJ, Burch PT, Jha P, Peyton JC, Kotwal GJ, Cheadle WG. Vaccinia virus complement control protein increases early bacterial clearance during experimental peritonitis. Surg Infect (Larchmt). 2003; 4(4):317-26.
          View in: PubMed
        52. Anderson JB, Smith SA, van Wijk R, Chien S, Kotwal GJ. Vaccinia virus complement control protein ameliorates hyperacute xenorejection by inhibiting xenoantibody binding. Transplant Proc. 2002 Dec; 34(8):3277-81.
          View in: PubMed
        53. Kotwal GJ, Lahiri DK, Hicks R. Potential intervention by vaccinia virus complement control protein of the signals contributing to the progression of central nervous system injury to Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov; 973:317-22.
          View in: PubMed
        54. Lahiri DK, Kotwal GJ, Farlow MR, Sima A, Kupsky W, Sarkar FH, Sambamurti K. The role of the carboxyl-terminal fragments of amyloid precursor protein in Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov; 973:334-9.
          View in: PubMed
        55. Smith SA, Krishnasamy G, Murthy KH, Cooper A, Bromek K, Barlow PN, Kotwal GJ. Vaccinia virus complement control protein is monomeric, and retains structural and functional integrity after exposure to adverse conditions. Biochim Biophys Acta. 2002 Jul 29; 1598(1-2):55-64.
          View in: PubMed
        56. Anderson JB, Smith SA, Kotwal GJ. Vaccinia virus complement control protein inhibits hyperacute xenorejection. Transplant Proc. 2002 Jun; 34(4):1083-5.
          View in: PubMed
        57. Hicks RR, Keeling KL, Yang MY, Smith SA, Simons AM, Kotwal GJ. Vaccinia virus complement control protein enhances functional recovery after traumatic brain injury. J Neurotrauma. 2002 Jun; 19(6):705-14.
          View in: PubMed
        58. Srisatjaluk R, Kotwal GJ, Hunt LA, Justus DE. Modulation of gamma interferon-induced major histocompatibility complex class II gene expression by Porphyromonas gingivalis membrane vesicles. Infect Immun. 2002 Mar; 70(3):1185-92.
          View in: PubMed
        59. Smith SA, Kotwal GJ. Immune response to poxvirus infections in various animals. Crit Rev Microbiol. 2002; 28(3):149-85.
          View in: PubMed
        60. Smith SA, Kotwal GJ. Virokines: novel immunomodulatory agents. Expert Opin Biol Ther. 2001 May; 1(3):343-57.
          View in: PubMed
        61. Al-Mohanna F, Parhar R, Kotwal GJ. Vaccinia virus complement control protein is capable of protecting xenoendothelial cells from antibody binding and killing by human complement and cytotoxic cells. Transplantation. 2001 Mar 27; 71(6):796-801.
          View in: PubMed
        62. Murthy KH, Smith SA, Ganesh VK, Judge KW, Mullin N, Barlow PN, Ogata CM, Kotwal GJ. Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell. 2001 Jan 26; 104(2):301-11.
          View in: PubMed
        63. Kotwal GJ. Approaches of the diagnosis of hepatitis viruses. Mol Biotechnol. 2000 Nov; 16(3):271-89.
          View in: PubMed
        64. Keeling KL, Hicks RR, Mahesh J, Billings BB, Kotwal GJ. Local neutrophil influx following lateral fluid-percussion brain injury in rats is associated with accumulation of complement activation fragments of the third component (C3) of the complement system. J Neuroimmunol. 2000 Jun 1; 105(1):20-30.
          View in: PubMed
        65. Smith SA, Mullin NP, Parkinson J, Shchelkunov SN, Totmenin AV, Loparev VN, Srisatjaluk R, Reynolds DN, Keeling KL, Justus DE, Barlow PN, Kotwal GJ. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense. J Virol. 2000 Jun; 74(12):5659-66.
          View in: PubMed
        66. Kotwal GJ. Poxviral mimicry of complement and chemokine system components: what's the end game? Immunol Today. 2000 May; 21(5):242-8.
          View in: PubMed
        67. Jonczy EA, Daly J, Kotwal GJ. A novel approach using an attenuated recombinant vaccinia virus to test the antipoxviral effects of handsoaps. Antiviral Res. 2000 Feb; 45(2):149-53.
          View in: PubMed
        68. Mahesh J, Daly J, Cheadle WG, Kotwal GJ. Elucidation of the early events contributing to zymosan-induced multiple organ dysfunction syndrome using MIP-1alpha, C3 knockout, and C5-deficient mice. Shock. 1999 Nov; 12(5):340-9.
          View in: PubMed
        69. Daly J, Lahiri DK, Kotwal GJ. Examination of the interactions of the amyloid precursor protein carboxyl terminus to intracellular protein: possible role in apoptosis. Prog Neuropsychopharmacol Biol Psychiatry. 1999 Jul; 23(5):861-75.
          View in: PubMed
        70. Lian RH, Kotwal GJ, Hunt LA, Wilson MA, Justus DE. Dextran sulfate inhibits IFN-gamma-induced Jak-Stat pathway in human vascular endothelial cells. Cell Immunol. 1999 Mar 15; 192(2):140-8.
          View in: PubMed
        71. Kotwal GJ. Virokines: mediators of virus-host interaction and future immunomodulators in medicine. Arch Immunol Ther Exp (Warsz). 1999; 47(3):135-8.
          View in: PubMed
        72. Daly J, Kotwal GJ. Pro-inflammatory complement activation by the A beta peptide of Alzheimer's disease is biologically significant and can be blocked by vaccinia virus complement control protein. Neurobiol Aging. 1998 Nov-Dec; 19(6):619-27.
          View in: PubMed
        73. Kotwal GJ, Miller CG, Justus DE. The inflammation modulatory protein (IMP) of cowpox virus drastically diminishes the tissue damage by down-regulating cellular infiltration resulting from complement activation. Mol Cell Biochem. 1998 Aug; 185(1-2):39-46.
          View in: PubMed
        74. Howard J, Justus DE, Totmenin AV, Shchelkunov S, Kotwal GJ. Molecular mimicry of the inflammation modulatory proteins (IMPs) of poxviruses: evasion of the inflammatory response to preserve viral habitat. J Leukoc Biol. 1998 Jul; 64(1):68-71.
          View in: PubMed
        75. Shchelkunov SN, Safronov PF, Totmenin AV, Petrov NA, Ryazankina OI, Gutorov VV, Kotwal GJ. The genomic sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins. Virology. 1998 Apr 10; 243(2):432-60.
          View in: PubMed
        76. Daly J, Lahiri DK, Justus DE, Kotwal GJ. Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's disease brain. Life Sci. 1998; 63(23):2121-31.
          View in: PubMed
        77. Kotwal GJ. Microorganisms and their interaction with the immune system. J Leukoc Biol. 1997 Oct; 62(4):415-29.
          View in: PubMed
        78. Adams G, Kuntz S, Rabalais G, Bratcher D, Tamburro CH, Kotwal GJ. Natural recovery from acute hepatitis C virus infection by agammaglobulinemic twin children. Pediatr Infect Dis J. 1997 May; 16(5):533-4.
          View in: PubMed
        79. Miller CG, Shchelkunov SN, Kotwal GJ. The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. Virology. 1997 Mar 3; 229(1):126-33.
          View in: PubMed
        80. Miller CG, Cook DN, Kotwal GJ. Two chemotactic factors, C5a and MIP-1alpha, dramatically alter the mortality from zymosan-induced multiple organ dysfunction syndrome (MODS): C5a contributes to MODS while MIP-1alpha has a protective role. Mol Immunol. 1996 Oct; 33(14):1135-7.
          View in: PubMed
        81. Lian RH, Kotwal GJ, Wellhausen SR, Hunt LA, Justus DE. IFN-gamma-induced MHC class II gene expression is suppressed in endothelial cells by dextran sulfate. J Immunol. 1996 Jul 15; 157(2):864-73.
          View in: PubMed
        82. Miller CG, Justus DE, Jayaraman S, Kotwal GJ. Severe and prolonged inflammatory response to localized cowpox virus infection in footpads of C5-deficient mice: investigation of the role of host complement in poxvirus pathogenesis. Cell Immunol. 1995 May; 162(2):326-32.
          View in: PubMed
        83. Kotwal GJ. Purification of virokines using ultrafiltration. Am Biotechnol Lab. 1994 Sep; 12(10):76-7.
          View in: PubMed
        84. Kotwal GJ. Routine laboratory diagnosis of hepatitis C virus infection. J Hepatol. 1993; 17 Suppl 3:S83-9.
          View in: PubMed
        85. McKenzie R, Kotwal GJ, Moss B, Hammer CH, Frank MM. Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis. 1992 Dec; 166(6):1245-50.
          View in: PubMed
        86. Kotwal GJ, Baroudy BM, Kuramoto IK, McDonald FF, Schiff GM, Holland PV, Zeldis JB. Detection of acute hepatitis C virus infection by ELISA using a synthetic peptide comprising a structural epitope. Proc Natl Acad Sci U S A. 1992 May 15; 89(10):4486-9.
          View in: PubMed
        87. Kotwal GJ, Rustgi VK, Baroudy BM. Detection of hepatitis C virus-specific antigens in semen from non-A, non-B hepatitis patients. Dig Dis Sci. 1992 May; 37(5):641-4.
          View in: PubMed
        88. Isaacs SN, Kotwal GJ, Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci U S A. 1992 Jan 15; 89(2):628-32.
          View in: PubMed
        89. Kotwal GJ, Isaacs SN, McKenzie R, Frank MM, Moss B. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science. 1990 Nov 9; 250(4982):827-30.
          View in: PubMed
        90. Isaacs SN, Kotwal GJ, Moss B. Reverse guanine phosphoribosyltransferase selection of recombinant vaccinia viruses. Virology. 1990 Oct; 178(2):626-30.
          View in: PubMed
        91. Kotwal GJ, Hügin AW, Moss B. Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. Virology. 1989 Aug; 171(2):579-87.
          View in: PubMed
        92. Kotwal GJ, Moss B. Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily. J Virol. 1989 Feb; 63(2):600-6.
          View in: PubMed
        93. Kotwal GJ, Moss B. Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant. Virology. 1988 Dec; 167(2):524-37.
          View in: PubMed
        94. Kotwal GJ, Moss B. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature. 1988 Sep 8; 335(6186):176-8.
          View in: PubMed
        95. Kotwal GJ, Buller ML, Wunner WH, Pringle CR, Ghosh HP. Role of glycosylation in transport of vesicular stomatitis virus envelope glycoprotein. A new class of mutant defective in glycosylation and transport of G protein. J Biol Chem. 1986 Jul 5; 261(19):8936-43.
          View in: PubMed
        96. Kotwal GJ, Capone J, Irving RA, Rhee SH, Bilan P, Toneguzzo F, Hofmann T, Ghosh HP. Viral membrane glycoproteins: comparison of the amino terminal amino acid sequences of the precursor and mature glycoproteins of three serotypes of vesicular stomatitis virus. Virology. 1983 Aug; 129(1):1-11.
          View in: PubMed
        For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
        Girish's Networks
        Click the "See All" links for more information and interactive visualizations!
        Concepts
        _
        Co-Authors
        _
        Similar People
        _
        Same Department
        Physical Neighbors
        _

        This is an official Page/Publication of the University of Massachusetts Worcester Campus
        Office of the Vice Provost for Research, 55 Lake Ave North, Worcester, Massachusetts 01655
        Questions or Comments? Email: publicaffairs@umassmed.edu Phone: 508-856-1572